Article PDF
Avoid common mistakes on your manuscript.
References
Kostadima L, Pentheroudakis G, Fountzilas G, Dimopoulos M, Pectasides D, Gogas H, Christodoulou C, Samantas E, Bafaloukos D, Arapantoni P, Kalofonos H, Papakostas P, Economopoulos T, Bamias A, Pavlidis N, Stropp U, Wirtz R, Hennig G (2006) Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat (in press) DOI: 10.1007/s10549-006-9240-x
Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok JB (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50:1986–1993
Span PN, Tjan-Heijnen VC, Manders P, van Tienoven D, Lehr J, Sweep FC (2006) High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 98:223–230
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Span, P.N., Tjan-Heijnen, V.C.G. & Sweep, F.C.G.J. Is survivin expression nevertheless related to disease outcome in breast cancer?. Breast Cancer Res Treat 103, 109 (2007). https://doi.org/10.1007/s10549-006-9350-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9350-5